Home Pharmaceutical asia-pacific-bronchiectasis-market

Pharmaceutical

Image

Asia-Pacific Bronchiectasis Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Mar 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 325
  • No of Figures: 56

Asia-Pacific Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral and Inhalation), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2028

Asia-Pacific Bronchiectasis Market Market Analysis and Insights : Asia-Pacific Bronchiectasis Market

Asia-Pacific bronchiectasis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.5% in the forecast period of 2021 to 2028 and is expected to reach USD 186.19 million by 2028. Technological advancement for disease testing and raising number of smokers and consumption of alcohol are the major drivers which propelled the demand of the market in the forecast period.

Bronchiectasis comprises features such increasing need for safe and effective product will impact in launching new product by the manufactures into the market which enhance its demand as well as increasing investment in research and development leads to the market growth. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative bronchiectasis products which is expected to provide various other opportunities in the bronchiectasis market. However, product recalls and complications in the treatment of bronchiectasis expected to restraint the market growth in the forecast period.

Bronchiectasis is a condition which leads to damage of lungs airways that is infection and inflammation occurs in the path were air comes in and out. The mucus gets collected in the airways which get clogged and bacteria start to grow in that region which leads to bronchiectasis. When this mucus gets collected in the airways and is not early diagnosed and treated it may cause damage to the lungs. This condition mainly occurs in women population and in the United States it was recorded that children with whooping cough generally have bronchiectasis.

Bronchiectasis can be congenital or acquired. The acquired one occurs mainly in infants and children whereas congenital occurs in adults. Cystic fibrosis, immunodeficiency disorders, allergic bronchopulmonary aspergillosis, and primary ciliary dyskinesia are some of the risk factors for bronchiectasis. Mainly antibiotics and oxygen therapies are recommended by the doctors and the patients have to live the condition as there is no permanent cure for the disease.

The Bronchiectasis market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Bronchiectasis Market Asia-Pacific Bronchiectasis Market Scope and Market Size

Bronchiectasis market is segmented on the based on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the bronchiectasis market is segmented into non-CF bronchiectasis and CF bronchiectasis. In 2021, non-CF bronchiectasis is expected to dominate the bronchiectasis market as it is the most common form of bronchiectasis which has been reported to affect most of the women and adult population.
  • On the basis of severity, the bronchiectasis market is segmented into mild to moderate and moderate-to-severe. In 2021, mild to moderate segment is expected to dominate the bronchiectasis market because bronchiectasis is a progressive respiratory disorder which is characterized by abnormally dilated airways, excessive sputum production and recurrent pulmonary infections among other symptoms which can be treated by novel drugs and other therapies.
  • On the basis of type, the bronchiectasis market is segmented into treatment and diagnosis. In 2021, treatment segment is expected to dominate the bronchiectasis market because bronchiectasis is the long term chronic disease and affected patient population are largely dependent on drugs in order to lead a healthy life.
  • On the basis of drugs type, the bronchiectasis market is segmented into branded and generic. In 2021, branded segment is expected to dominate the bronchiectasis market as most of the companies are engaged in manufacturing of branded drugs. Moreover increasing demand of safe product raises the demand of branded drugs among patient population.
  • On the basis of route of administration, the bronchiectasis market is segmented into oral, parenteral, and inhalation. In 2021, inhalation segment is expected to dominate the bronchiectasis market because bronchiectasis is a lung associated inflammatory disease which can rapidly treat with drugs directly targeting lung airways.  
  • On the basis of end user, the bronchiectasis market is segmented into hospitals, clinics, home healthcare, and others. In 2021, hospitals segment is dominating the bronchiectasis market because hospitals have advanced diagnostic tools used for accurate diagnosis of bronchiectasis. Moreover skilled professionals at hospitals allow effective intravenous drug delivery which acts as another factor boosting the market growth.
  • On the basis of distribution channel, the bronchiectasis market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy is expected to dominate the bronchiectasis market as hospital pharmacy have has wide range of products as per the patients need and demand.

Bronchiectasis Market Country Level Analysis

The bronchiectasis market is analyzed and market size information is provided on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.

The countries covered in the bronchiectasis market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific.

Treatment segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because bronchiectasis is the life-long disease and required continuous treatment. The overall treatment cost for the bronchiectasis is quite high and now consider in some reimbursement policies. Japan is leading the growth of the Asia-Pacific market and treatment segment is dominating in this country due to technological advancement for the diagnosis and treatment of respiratory diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Technological Advancement for Disease Testing and Increase in Research Regarding the Bronchiectasis Disease are Boosting the Market Growth of Bronchiectasis

Bronchiectasis market also provides you with detailed market analysis for every country growth in bronchiectasis industry with bronchiectasis drugs sales, impact of advancement in the bronchiectasis technology and changes in regulatory scenarios with their support for the bronchiectasis market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Bronchiectasis Market Share Analysis

Bronchiectasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to bronchiectasis market.

The major companies which are dealing in the bronchiectasis are Abbott, HERSILL, Inogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc, Ache Laboratories Farmaceuticos S.A., Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. Reddy’s Laboratories Ltd., Viatris Inc. and Cipla Inc., among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the bronchiectasis market.

  • In December 2018, AstraZeneca received approval for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) indicated for treatment of severe symptoms associated with COPD. This product has already received approval by regulatory authorities of Canada, the U.S, Australia, Taiwan and Turkey. This new approval enhanced the product sales which has positively impacted the company’s revenue.
  • In February 2018, GlaxoSmithKline plc. launched Flunase, in Japan. Flunase is the first fluticasone propionate-based treatment launched in Japan and is indicated for relieving the inflammatory symptoms associated with respiratory problems. This product launch thus allowed the company to fulfil the unmet patients demand suffering from bronchiectasis in Japan and boosted the company’s revenue by positive increase of product sales.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the bronchiectasis market which also provides the benefit for organization to improve their offering for bronchiectasis.

SKU-

LIST OF TABLES 

TABLE 1 ASIA PACIFIC BRONCHIECTASIS MARKET, PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC

TABLE 4 THE PRICE OF X-RAY MACHINE

TABLE 5 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 6 ASIA PACIFIC NON-CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA PACIFIC CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 9 ASIA PACIFIC MILD TO MODERATE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 ASIA PACIFIC MODERATE TO SEVERE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 13 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 ASIA PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 ASIA PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 ASIA PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 ASIA PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 ASIA PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 19 ASIA PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 ASIA PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 21 ASIA PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 22 ASIA PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 23 ASIA PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 24 ASIA PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 25 ASIA PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 26 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 28 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 29 ASIA PACIFIC BRANDED IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 ASIA PACIFIC GENERICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 32 ASIA PACIFIC INHALATION IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 ASIA PACIFIC ORAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 ASIA PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 ASIA PACIFIC PARENTERAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 ASIA PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 37 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 38 ASIA PACIFIC HOSPITALS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 ASIA PACIFIC CLINICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 ASIA PACIFIC HOME HEALTHCARE IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 ASIA PACIFIC HOSPITAL PHARMACY IN BRONCHIECTASIS MARKET, REGION, 2019-2028 (USD MILLION)

TABLE 44 ASIA PACIFIC RETAIL PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 ASIA PACIFIC ONLINE PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 ASIA PACIFIC BRONCHIECTASIS MARKET, BY REGION , 2021-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 ASIA-PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 ASIA-PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 ASIA-PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 ASIA-PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 ASIA-PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 67 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 68 ASIA-PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 69 ASIA-PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 71 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 72 JAPAN BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 73 JAPAN BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 74 JAPAN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 JAPAN TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 JAPAN TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 JAPAN TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 JAPAN TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 JAPAN TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 JAPAN TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 JAPAN TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 82 JAPAN TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 83 JAPAN TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 84 JAPAN TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 85 JAPAN TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 86 JAPAN TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 87 JAPAN TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 88 JAPAN DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 JAPAN BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 90 JAPAN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 JAPAN ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 92 JAPAN PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 93 JAPAN BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 94 JAPAN BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 CHINA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 96 CHINA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 97 CHINA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 98 CHINA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 99 CHINA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 100 CHINA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 101 CHINA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 CHINA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 103 CHINA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 CHINA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 CHINA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 106 CHINA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 107 CHINA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 108 CHINA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 109 CHINA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 CHINA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 CHINA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 112 CHINA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 113 CHINA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 114 CHINA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 115 CHINA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 116 CHINA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 117 CHINA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 118 INDIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 119 INDIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 120 INDIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 INDIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 INDIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 123 INDIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 124 INDIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 125 INDIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 126 INDIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 127 INDIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 INDIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 129 INDIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 130 INDIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 INDIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 132 INDIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 133 INDIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 134 INDIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 135 INDIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 136 INDIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 137 INDIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 138 INDIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 139 INDIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 140 INDIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 141 AUSTRALIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 142 AUSTRALIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 143 AUSTRALIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 144 AUSTRALIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 145 AUSTRALIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 146 AUSTRALIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 147 AUSTRALIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 148 AUSTRALIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 149 AUSTRALIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 150 AUSTRALIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 151 AUSTRALIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 152 AUSTRALIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 153 AUSTRALIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 154 AUSTRALIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 155 AUSTRALIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 156 AUSTRALIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 157 AUSTRALIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 158 AUSTRALIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 159 AUSTRALIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 160 AUSTRALIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 161 AUSTRALIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 162 AUSTRALIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 163 AUSTRALIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 164 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 165 SOUTH KOREAT BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 166 SOUTH KOREA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 167 SOUTH KOREA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 168 SOUTH KOREA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 169 SOUTH KOREA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 170 SOUTH KOREA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 171 SOUTH KOREA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 172 SOUTH KOREA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 173 SOUTH KOREA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 174 SOUTH KOREA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 175 SOUTH KOREA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 176 SOUTH KOREA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 177 SOUTH KOREA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 178 SOUTH KOREA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 179 SOUTH KOREA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 180 SOUTH KOREA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 181 SOUTH KOREA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 182 SOUTH KOREA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 183 SOUTH KOREA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 184 SOUTH KOREA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 185 SOUTH KOREA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 186 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 187 SINGAPORE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 188 SINGAPORE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 189 SINGAPORE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 190 SINGAPORE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 191 SINGAPORE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 192 SINGAPORE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 193 SINGAPORE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 194 SINGAPORE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 195 SINGAPORE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 196 SINGAPORE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 197 SINGAPORE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 198 SINGAPORE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 199 SINGAPORE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 200 SINGAPORE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 201 SINGAPORE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 202 SINGAPORE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 203 SINGAPORE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 204 SINGAPORE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 205 SINGAPORE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 206 SINGAPORE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 207 SINGAPORE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 208 SINGAPORE BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 209 SINGAPORE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 210 MALAYSIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 211 MALAYSIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 212 MALAYSIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 213 MALAYSIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 214 MALAYSIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 215 MALAYSIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 216 MALAYSIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 217 MALAYSIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 218 MALAYSIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 219 MALAYSIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 220 MALAYSIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 221 MALAYSIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 222 MALAYSIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 223 MALAYSIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 224 MALAYSIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 225 MALAYSIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 226 MALAYSIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 227 MALAYSIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 228 MALAYSIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 229 MALAYSIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 230 MALAYSIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 231 MALAYSIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 232 MALAYSIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 233 THAILAND BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 234 THAILAND BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 235 THAILAND BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 236 THAILAND TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 237 THAILAND TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 238 THAILAND TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 239 THAILAND TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 240 THAILAND TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 241 THAILAND TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 242 THAILAND TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 243 THAILAND TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 244 THAILAND TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 245 THAILAND TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 246 THAILAND TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 247 THAILAND TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 248 THAILAND TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 249 THAILAND DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 250 THAILAND BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 251 THAILAND BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 252 THAILAND ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 253 THAILAND PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 254 THAILAND BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 255 THAILAND BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 256 INDONESIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 257 INDONESIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 258 INDONESIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 259 INDONESIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 260 INDONESIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 261 INDONESIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 262 INDONESIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 263 INDONESIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 264 INDONESIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 265 INDONESIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 266 INDONESIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 267 INDONESIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 268 INDONESIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 269 INDONESIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 270 INDONESIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 271 INDONESIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 272 INDONESIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 273 INDONESIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 274 INDONESIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 275 INDONESIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 276 INDONESIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 277 INDONESIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 278 INDONESIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 279 PHILIPPINES BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 280 PHILIPPINES BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 281 PHILIPPINES BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 282 PHILIPPINES TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 283 PHILIPPINES TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 284 PHILIPPINES TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 285 PHILIPPINES TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 286 PHILIPPINES TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 287 PHILIPPINES TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 288 PHILIPPINES TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 289 PHILIPPINES TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 290 PHILIPPINES TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 291 PHILIPPINES TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 292 PHILIPPINES TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 293 PHILIPPINES TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 294 PHILIPPINES TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 295 PHILIPPINES DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 296 PHILIPPINES BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 297 PHILIPPINES BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 298 PHILIPPINES ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 299 PHILIPPINES PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 300 PHILIPPINES BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 301 PHILIPPINES BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 302 VIETNAM BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 303 VIETNAM BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 304 VIETNAM BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 305 VIETNAM TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 306 VIETNAM TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 307 VIETNAM TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 308 VIETNAM TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 309 VIETNAM TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 310 VIETNAM TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 311 VIETNAM TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 312 VIETNAM TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 313 VIETNAM TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 314 VIETNAM TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 315 VIETNAM TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 316 VIETNAM TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 317 VIETNAM TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 318 VIETNAM DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 319 VIETNAM BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 320 VIETNAM BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 321 VIETNAM ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 322 VIETNAM PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 323 VIETNAM BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 324 VIETNAM BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 325 REST OF ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

 

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

BROWSE RELATED REPORTS

Global Bronchiectasis Market – Industry Trends and Forecast to 2031
Middle East and Africa Bronchiectasis Market – Industry Trends and Forecast to 2030
Europe Bronchiectasis Market – Industry Trends and Forecast to 2028
North America Bronchiectasis Market – Industry Trends and Forecast to 2028
Global Non-Cystic Fibrosis Bronchiectasis Market - Industry Trends and Forecast to 2028

BROWSE RELATED Blogs

Global Bronchiectasis Market is growing with 6.0% CAGR in the forecast period of 2021 to 2028
North America Bronchiectasis Market is Growing with 6.1% CAGR in the Forecast Period of 2021 to 2028

BROWSE RELATED Press Release

Rising Number of Smokers and Consumption of Alcohol Drive the Demand for Bronchiectasis Market
AstraZeneca, GlaxoSmithKline Plc and Teva Pharmaceutical Industries Ltd are Dominating the North America Bronchiectasis Market in 2020.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future